Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment.

摘要

To the Editor: Albright et al. (2010) should be congratulated for their multistate physician survey study examining barriers for buprenorphine treatment adoption, which adds to a growing body of literature on various system-level and provider-level factors limiting integration of buprenorphine treatment in practice (Gunderson et al., 2006; Kissin et al., 2006; Cunningham et al., 2007; Walley et al., 2008; Barry et al., 2009; Netherland et al., 2009). Given the effectiveness of office-based opioid treatment (OBOT) yet persistent national gap in treatment availability, studies such as theirs are needed to help elucidate potential targets to facilitate implementation in clinical practice. Eleven potential barriers were identified during survey development. However, a major one was omitted: the challenge of buprenorphine induction.